MicroRNA-6511a-3 (human) (miR-6511a-3)

MicroRNA-6511a-3 is a member of the microRNA (miRNA) family, a class of small, non-coding RNAs that regulate gene expression post-transcriptionally, typically by binding to complementary sequences in target messenger RNAs (mRNAs) and promoting their degradation or repressing their translation[6][5]. MicroRNAs are transcribed as primary transcripts (pri-miRNAs), processed in the nucleus by the Drosha-DGCR8 complex, exported to the cytoplasm, and further processed by Dicer to produce mature functional miRNAs[5][1][2]. The mature miRNA is incorporated into the RNA-induced silencing complex (RISC), where it guides the complex to target mRNAs[5]. The "3" in miR-6511a-3 designates the mature miRNA processed from the 3' arm of the precursor. No disease, therapeutic, or drug interaction information specific to microRNA-6511a-3 was found in the available data. There is also no evidence this molecule is a therapeutic target or biomarker, nor is there specific functional or safety data—its roles are inferred based on the general characteristics of microRNAs[5][6]. Human microRNAs are systematically named (e.g., hsa-mir-6511a-3; "hsa" denotes Homo sapiens)[6]. However, "miR-6511a-3" is not well-characterized in terms of unique functional or clinical significance, and it is not listed as a validated therapeutic target. The name may also be referencing the precursor miRNA gene ("MIR6511A3") or its mature RNA product, but in either context, substantive biological or pathway data is lacking. Therefore, this entry is considered *incorrect as a therapeutic target* due to absence of evidence for specific targetability, biological annotation, or therapeutic application.

Other names

hsa-mir-6511a-3MIR6511A3MIR6511A-3microRNA mir-6511a-3